Roy D. Baynes sold $2.8M of NTRA
director at Natera, Inc.. 12,780 shares at an average of $219.85, traded Nov 19, 2025, filed Nov 21, 2025.
Score components
- +15RoleDirector
- +25Trade size$2.8M at market
- +20Share of holdings soldSold 54% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.6%, 3m -8.0%, 6m -11.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001680739-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | MOption exercise Common Stock10b5-1 | +5,112 | $40.93 | $209k | 23,471 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stock10b5-1 | -1,250 | $213.47 | $267k | 22,221 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stock10b5-1 | -1,727 | $214.79 | $371k | 20,494 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stock10b5-1 | -2,135 | $216.07 | $461k | 18,359 | Nov 21, 2025 |
| Nov 20, 2025 | MOption exercise Common Stock10b5-1 | +600 | $40.93 | $25k | 18,959 | Nov 21, 2025 |
| Nov 20, 2025 | MOption exercise Common Stock10b5-1 | +7,068 | $41.19 | $291k | 26,027 | Nov 21, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stock10b5-1 | -1,184 | $220.14 | $261k | 24,843 | Nov 21, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stock10b5-1 | -900 | $221.81 | $200k | 23,943 | Nov 21, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stock10b5-1 | -1,800 | $222.90 | $401k | 22,143 | Nov 21, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stock10b5-1 | -1,900 | $223.90 | $425k | 20,243 | Nov 21, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stock10b5-1 | -1,884 | $224.89 | $424k | 18,359 | Nov 21, 2025 |
| Nov 19, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,112 | $0.00 | $0 | 600 | Nov 21, 2025 |
| Nov 20, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -600 | $0.00 | $0 | 0 | Nov 21, 2025 |
| Nov 20, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -7,068 | $0.00 | $0 | 0 | Nov 21, 2025 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 40Moderate | Natera, Inc. | John Fesko PRESIDENT, CHIEF BUS. OFFICER | $2.1M 6,517 shares | -3% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $2.0M 6,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.